Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy

Completed · Phase 2

Conditions studied: Head and Neck Cancer

In brief

The purpose of this research study is to test the safety and efficacy of nivolumab after salvage resection in head and neck cancer in patients that have previously received definitive radiation with or without chemotherapy.

Key facts

Study ID

NCT03355560

Run by

Trisha Wise-Draper

People needed

39

Starts

2017-12-06

Expected to finish

2026-04-15

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Prior definitive therapy with radiation (with or without prior surgical resection and/or chemotherapy) who have underwent salvage resection with curative intent and have no other curable options
• Pre-operative scans including chest imaging preferably PET/CT and CT neck w/contrast. MRI neck is acceptable if contrast contraindicated.
• Able to provide archived biopsy or resected tissue.
• Adequate performance status and labs.

You may not qualify if…

• Patients who did not receive at least radiotherapy as prior definitive treatment.
• Patients who have gross measurable residual disease after surgery or those who underwent surgery for palliative purposes i.e. for symptom control.
• Has nasopharyngeal or sinonasal carcinoma.
• Has confirmed metastatic disease.

Where it is running

• Karmanos Cancer Institute — Detroit, Michigan, United States
• UC Health — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.